Lv5
1600 积分 2025-05-20 加入
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
1天前
已完结
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
4天前
已完结
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
14天前
已完结
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
1个月前
已完结
Factors that can make overall survival unreliable as a clinical trial outcome – Authors' reply
1个月前
已完结
Overall survival assessment in cancer drug trials: a luxury or a necessity?
1个月前
已完结
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti‐CD20): a retrospective cohort analysis
1个月前
已完结
Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma
1个月前
已完结
Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome
2个月前
已完结
Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis
4个月前
已完结
皖公网安备34019202002308
